TeamDrive
RUS

The import of finished medicines to Russia exceeded 244 billion rubles in H1 2018

24 August 2018

GMP News

According to the results of the first half of 2018, imports of finished mediсinal drugs to Russia amounted to 244.3 billion rubles (in prices of release for free circulation). Deliveries of in-bulk products during the same period reached 52 billion rubles.

Year over year growth comparing to the same period in 2017 when calculating in rubles amounted to 2% for finished forms, the supply of bulk products increased by 22% for the year. The total volume of medicines imported since the beginning of the year increased in ruble terms by 5%.

The natural volume of imports of finished medicines for the period January-June of this year is 878.7 million packs, which is 7% less than in the same period in 2017. In-bulk deliveries for the period amounted to 2.12 billion minimal dosing units (MDU). The dynamics feels better (relative to the FMP), but retains a negative value (-0.4%). The total volume of supplies for all forms for the first half of the year was 18.5 billion MDU, long-term dynamics therefore is also in the red (-4%).

Among the top 20 finished medicines, leading in terms of imports in the first half of the year, antiviral drugs active against HIV show the maximum dynamics: Tivicay (for the year the ruble volume of deliveries increased 20 times) and Eviplera (deliveries increased 3 times). As regards in-bulk production, the two top positions, both in share and in terms of dynamics, are Revlimid formulations (imports in rubles increased more than 200 times during the year) and Concor (shipments increased 16 times).

Source


Previous publication Next publication

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more